Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovastatin and Interferon for Melanoma
NCT00963664Phase 2Withdrawn
- Sponsor
- NeoPlas Innovation
- Start
- Dec 2009
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lovastatin in Malignant Melanoma (MM), sponsored by NeoPlas Innovation. Primary endpoints: Overall Survival at 5 years and Time to Progression of Disease at 5 years. Planned start Dec 2009; status: withdrawn.
02
Drugs
lovastatin
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00963664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00963664.